About the 2024 Event
With increased liquid biopsy approvals and investments, there remains a critical need, their potential for early disease detection, real-time monitoring and personalized treatment has reached an inflection point. To further increase patient access to precision drugs, there remains a critical need for higher sensitivity, clinical validation, regulatory harmonization and improved market access for patients.
As such, the 8th Liquid Biopsy for Precision Oncology Summit returns as the definitive industry-led forum to address these challenges and will cover the full end-to-end of liquid biopsy development with exclusive content including:
Exploring innovative biomarkers for precision oncology to enhance disease progression understanding for guided treatment responses
Utilizing novel multiomic and AI/ML technologies to detect circulating biomarkers at an increased accuracy to enable early and precise disease prognosis
Benchmarking surrogate endpoints in clinical trials to predict accurate clinical outcomes and tailor precision oncology for improved survival rates.
Navigating the reimbursement and regulatory landscapes through cross sector collaborations to expand commercialization and access to biomarker testing
Join the end-to-end most comprehensive event for the liquid biopsy community alongside 250+ Heads, VPs and Directors of Translational Medicine, Precision Oncology, Bioinformatics, Computation, Companion Diagnostics and more to contribute to the field’s advancements, support commercialization, market access and reimbursement efforts to improve disease diagnosis, monitoring, and treatment options to improve patient outcomes.
What New in 2024?
Your Checklist to Accelerate Liquid Biopsy Pipelines
Transform assay sensitivity, specificity and accuracy using multiomics and AI/ML to detect clinically actionable biomarkers for enhanced disease prognosis and diagnosis with BioAtla, AbbVie, Genentech & Lantern Pharma
Harness innovative liquid biopsy applications in early oncology assets to expedite robust drug development to revolutionise cancer treatment with Bristol Myers Squibb & Zai Labs
Accelerate the commercialization of liquid biopsy tests by adequately navigating global regulatory and reimbursement landscapes to broaden patient access and adoption with Independence Blue Cross, Novartis & Johnson & Johnson Innovative Medicines
Bridge discovery and translational to improve biomarker and clinical validation to drive wide-spread and cost-effective implementation of liquid biopsies with Regeneron & GSK
Meet and learn from pioneering diagnostic and solution providers leaders who share the same goal of advancing precision medicine for patients such as Guardant Health, Foundation Medicine & Grail